Logo for Trevi Therapeutics Inc

Trevi Therapeutics Inc Investor Relations Material

Latest events

Logo for Trevi Therapeutics Inc

Q3 2023

Trevi Therapeutics Inc
Logo for Trevi Therapeutics Inc

Q3 2023

9 Nov, 2023
Logo for Trevi Therapeutics Inc

Q2 2023

10 Aug, 2023
Access the full event backlog
Slides, Transcripts, and Reports from over 8,000 public companies
Trevi Therapeutics, Inc a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation.